Lyra Therapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Lyra Therapeutics's earnings have been declining at an average annual rate of -34.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 51.7% per year.
Informazioni chiave
-34.1%
Tasso di crescita degli utili
92.5%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore | 6.0% |
Tasso di crescita dei ricavi | 51.7% |
Rendimento del capitale proprio | -327.3% |
Margine netto | -5,570.9% |
Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Ripartizione dei ricavi e delle spese
Come Lyra Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
---|---|---|---|---|
30 Jun 24 | 2 | -101 | 20 | 0 |
31 Mar 24 | 2 | -69 | 20 | 0 |
31 Dec 23 | 2 | -63 | 19 | 0 |
30 Sep 23 | 1 | -62 | 19 | 0 |
30 Jun 23 | 1 | -61 | 17 | 0 |
31 Mar 23 | 1 | -60 | 18 | 0 |
31 Dec 22 | 1 | -55 | 18 | 0 |
30 Sep 22 | 2 | -55 | 18 | 0 |
30 Jun 22 | 1 | -51 | 17 | 0 |
31 Mar 22 | 1 | -48 | 16 | 0 |
31 Dec 21 | 0 | -44 | 14 | 0 |
30 Sep 21 | 0 | -37 | 16 | 0 |
30 Jun 21 | 0 | -32 | 14 | -5 |
31 Mar 21 | 0 | -26 | 11 | -3 |
31 Dec 20 | 0 | -22 | 10 | 0 |
30 Sep 20 | 0 | -20 | 8 | 3 |
30 Jun 20 | 0 | -18 | 6 | 11 |
31 Mar 20 | 0 | -17 | 5 | 12 |
31 Dec 19 | 0 | -17 | 4 | 12 |
31 Dec 18 | 1 | -6 | 4 | 5 |
Guadagni di qualità: LYRA is currently unprofitable.
Margine di profitto in crescita: LYRA is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: LYRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accelerare la crescita: Unable to compare LYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: LYRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendimento del capitale proprio
ROE elevato: LYRA has a negative Return on Equity (-327.31%), as it is currently unprofitable.